Anlotinib in locally advanced or metastatic radioiodinerefractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial
机构：[1]Department of Medical Oncology, National Cancer Center / National ClinicalResearch Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciencesand Peking Union Medical College, Beijing, China[2]Department of Thyroid and NeckOncology, Tianjin Medical University Cancer Institute and Hospital, National ClinicalResearch Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin,Tianjin’s Clinical Research Center for Cancer, Tianjin, China[3]Head and Neck Surgery(Department), Jiangsu Cancer Hospital (Jiangsu Institute of Cancer Research, NanjingMedical University Affiliated Cancer Hospital), Nanjing, China[4]Thyroid TumourInternal Medicine Department / Nuclear Medicine Center, Hunan Cancer Hospital,Changsha, China[5]Department of Medical Oncology, Jilin Cancer Hospital, Changchun,China[6]Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou,China[7]Department of Head, Neck and Thyroid Surgery, Zhejiang Provincial People’sHospital, People’s Hospital of Hangzhou Medical College, Hangzhou, China[8]Thyroid &Head and Neck Surgery, Affiliated Cancer Hospital of Zhengzhou University HenanCancer Hospital, Henan, China河南省肿瘤医院[9]Thyroid Surgery Ward, Harbin Medical UniversityCancer Hospital, Harbin, China[10]Department of Head &Neck Surgery, Tumor Hospitalof China Medical University, Liaoning Tumor Hospital & Institute, Shenyang, China[11]Head and Neck Cancer Center, Chongqing University Cancer Hospital, ChongqingCancer Hospital, Chongqing, China[12]Department of Nuclear Medicine, West ChinaHospital, Sichuan University, Sichuan, China[13]Department of Otolaryngology Headand Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China首都医科大学附属同仁医院[14]Head and Neck Department, Fujian Cancer Hospital, Fuzhou, China[15]Department ofThyroid Surgery, First Affiliated Hospital of Kunming Medical University, Kunming,China外科科室普通外科普通外五科(甲状腺疾病诊疗中心)昆明医科大学附属第一医院[16]Head and Neck Surgery, National Cancer Center / National Clinical ResearchCenter for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and PekingUnion Medical College, Beijing, China[17]Department for VIP, National Cancer Center /National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy ofMedical Sciences and Peking Union Medical College, Beijing, China
第一作者机构：[1]Department of Medical Oncology, National Cancer Center / National ClinicalResearch Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciencesand Peking Union Medical College, Beijing, China
推荐引用方式(GB/T 7714)：
Y. Chi,M. Gao,Y. Zhang,et al.Anlotinib in locally advanced or metastatic radioiodinerefractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial[J].ANNALS OF ONCOLOGY.2020,31:S1347-S1347.doi:10.1016/j.annonc.2020.10.259.
APA：
Y. Chi,M. Gao,Y. Zhang,F. Shi,Y. Cheng...&P. Tang.(2020).Anlotinib in locally advanced or metastatic radioiodinerefractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial.ANNALS OF ONCOLOGY,31,
MLA：
Y. Chi,et al."Anlotinib in locally advanced or metastatic radioiodinerefractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial".ANNALS OF ONCOLOGY 31.(2020):S1347-S1347
医学